SF5162

Purpose

• Reorganize who regulates health plans and related purchasers in Minnesota and improve cost oversight in health care and financial services.
• Create stronger price transparency and oversight for prescription drugs with high costs.
• Update licensing and regulatory rules for nondepository financial institutions, virtual currency activities, and related lending operations.
• Reallocate budgetary responsibilities and adjust state spending accordingly.

Main provisions

• Health plan regulation and funding (Article 1)

  • Transfers regulatory responsibility for health maintenance organizations (HMOs) and county-based purchasers to the Commissioner of Commerce.
  • Provides an appropriation of 1,750,000 from the General Fund in fiscal year 2027 to support this regulation.
  • Requires corresponding reductions in the Department of Health’s budget (general fund and state government special revenue) to account for the transfer; these reductions are ongoing.

• Prescription drug affordability oversight (Article 2)

  • Updates conflict-of-interest rules for members of the Prescription Drug Affordability Advisory Council and related boards.
  • Requires disclosure of conflicts before service or appointment and mandates recusal from decisions involving drugs with conflicts.
  • Establishes criteria for identifying prescription drugs that may impact affordability, including:
  • Brand-name drugs or biologics with large price increases (WAC up > 15% or > $3,000 in a 12-month period, CPI-adjusted).
  • High-priced drugs (WAC ≥ $60,000 per year or per course of treatment).
  • Biosimilar drugs not at least 20% cheaper than the reference biologic at launch.
  • Generics with substantial price increases after CPI adjustments.
  • The board, with the advisory council and health department, may identify other drugs that could cause affordability challenges (e.g., drugs for public health emergencies).
  • Drug names and price information identified under these rules will be made public, with protections for proprietary information and other data that are not public or that qualify as trade secrets.
  • Repeals two existing sections related to the current drug affordability framework.

• Nondepository financial institutions and lending (Article 3)

  • Expands and clarifies the authority of Commerce to oversee and engage with nondepository lenders and related financial activities, including:
  • Authority to make certain loans and advances of credit and to purchase obligations secured by government-insured backing (e.g., FHA, VA, Farmers Home Administration) or other federally backed programs.
  • Authority to purchase or participate in loans and advances, including reverse mortgages, without certain former statutory limits, and to engage with federal agency-backed loans.
  • Defines key terms for consumer lending and credit (e.g., consumer loan, credit card, finance charge, loan, APR, etc.) to standardize regulatory language.
  • Updates to consumer lending rules, including consumer small loans (defined as up to $350, short-term, unsecured, repayable in a single installment) and related licensing requirements.
  • Virtual currency activities:
  • Adds specific requirements for virtual currency business activities, including tangible net worth calculations, recordkeeping for five years, and detailed transaction and reconciliation records.
  • Requires general ledger maintenance, transaction-level records, and compliance documentation to be kept and accessible for regulatory purposes.
  • Licensing and regulatory alignment:
  • Clarifies licensing requirements for certain lenders and aligns state rules with federal programs and agencies.
  • Clarifies exceptions for certain government or federally regulated entities that purchase or take assignments of mortgage loans (not required to be licensed under certain circumstances).
  • Miscellaneous licensing provisions:
  • Requires licenses to be posted and clearly displayed, including on websites for Internet-based operations.
  • Maintains ongoing applicability of other related licensing provisions when applicable to loans regulated by Minnesota law.

Significant changes to existing law

• Health regulation

  • Moves HMO and county-based purchaser regulation from the Department of Health to the Commissioner of Commerce, altering state supervision structure for health plan regulation.

• Drug affordability transparency

  • Introduces explicit public disclosure of prices for identified drugs, with safeguards for confidential information.
  • Establishes concrete thresholds and criteria for identifying high-cost or affordability-challenging drugs, connected to WAC and CPI adjustments.

• Financial services regulation

  • Broadly expands the scope of nondepository lenders that the Commissioner of Commerce can regulate, including mortgage-related activities and government-backed loan programs.
  • Creates explicit, standardized definitions for consumer lending terms to unify regulatory interpretation.
  • Adds rigorous recordkeeping and reporting requirements for virtual currency business activities, subject to regulatory oversight.
  • Provides licensing clarity and certain carveouts for federal or federally supervised entities engaging in mortgage-related activities.

Impact and who it affects

• Health care and insurance stakeholders (HMOs, county-based purchasers, patients, and providers) will see regulatory structure changes and potential shifts in oversight and fees.
• Prescription drug manufacturers, wholesalers, and health systems will face new price transparency measures and public reporting requirements for selected medicines.
• Financial institutions, mortgage lenders, and nondepository lenders (including those dealing with virtual currencies) will see updated licensing processes, expanded regulatory authority, and new data-retention obligations.
• Consumers could experience changes in access to credit products and improved visibility into drug pricing, depending on implementation.

Relevant terms

• Health maintenance organization (HMO)
• County-based purchaser
• Commissioner of Commerce
• Department of Health
• Prescription Drug Affordability Advisory Council
• Conflict of interest
• Recusal
• Wholesale Acquisition Cost (WAC)
• CPI (Consumer Price Index)
• Biosimilar
• Generic drug
• Public data / trade secret
• Proprietary information
• Nondepository financial institution
• Loan
• Consumer loan
• Credit card
• Finance charge
• Virtual currency
• Tangible net worth
• National Mortgage Licensing System (NMLS)
• License / licensing
• Mortgage loan
• FHA / VA / Farmers Home Administration (federal loan programs)
• Recordkeeping / general ledger
• Security interest / lien

Relevant Terms - HMO, county-based purchaser, Commissioner of Commerce, Department of Health, WAC, CPI, biosimilar, generic, conflict of interest, recusal, virtual currency, tangible net worth, NMLS, license, mortgage loan, recordkeeping, trade secret, public data, finance charge, consumer loan, loan.